We are live on ! Find out more
COLL icon

Collegium Pharmaceutical

167 hedge funds and large institutions have $575M invested in Collegium Pharmaceutical in 2022 Q3 according to their latest regulatory filings, with 33 funds opening new positions, 54 increasing their positions, 48 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

8,256% more call options, than puts

Call options by funds: $1.34M | Put options by funds: $16K

50% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 22

13% more repeat investments, than reductions

Existing positions increased: 54 | Existing positions reduced: 48

6% more funds holding

Funds holding: 157167 (+10)

2.17% less ownership

Funds ownership: 107.24%105.08% (-2.2%)

11% less capital invested

Capital invested by funds: $646M → $575M (-$71M)

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
167
Holders Change
+10
Holders Change %
+6.37%
% of All Funds
2.87%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
33
Increased
54
Reduced
48
Closed
22
Calls
$1.34M
Puts
$16K
Net Calls
+$1.32M
Net Calls Change
+$890K

COLL Hedge Fund Activity: Q3 2022 in Review

167 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Collegium Pharmaceutical (COLL) for Q3 2022, worth a combined $575M — down 11% from $646M a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new COLL positions and 22 closed out — a net gain of 11 holders — while 54 added to existing stakes and 48 trimmed.

The largest buyer was Millennium Management, adding an estimated $8.07M. The largest seller was Royce & Associates, cutting an estimated $7.62M.

  • 167 institutional investors held Collegium Pharmaceutical (COLL) as of Q3 2022, up from 157 in Q2 2022.
  • Funds reported $575M of Collegium Pharmaceutical stock for Q3 2022, down 11% quarter-over-quarter.
  • 33 funds opened new Collegium Pharmaceutical positions in Q3 2022 and 22 closed out, a net change of +11 holders.
  • The largest Collegium Pharmaceutical buyer in Q3 2022 was Millennium Management, an estimated $8.07M added.
  • The largest Collegium Pharmaceutical seller in Q3 2022 was Royce & Associates, an estimated $7.62M sold.

Based on aggregated 13F filings for Q3 2022.